CAR-T therapies are a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies, but many challenges remain, such as changes in CD19-presentation on the cancer cells and antigen loss. To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B cell-specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR-T cell that simultaneously targets CD19 and CD22. In this webinar, Dr. David Miklos, Chief Clinical Director of Blood and Marrow Transplantation and Cellular Therapy at Stanford University, discusses recent advances in bispecific CAR-T therapy development and how Isoplexis’ functional phenotyping provides critical functional biomarkers for characterizing CAR-T cell product quality.
- The T-cell dependent benefits of CAR-T therapy
- Treatment schema for CAR-T cell therapy
- Simultaneous targeting of two tumor antigens to overcome antigen loss and improve efficacy
- Is there an optimal T cell for CAR-T therapy?
Watch now below: